

## Platinum-A Retroviral Packaging Cell Line, Amphotropic

**CATALOG NUMBER:** RV-102

**STORAGE:** Liquid nitrogen

*Note: For best results begin culture of cells immediately upon receipt. If this is not possible, store at -80°C until first culture. Store subsequent cultured cells long term in liquid nitrogen.*


**QUANTITY & CONCENTRATION:** 1.0 mL,  $>3 \times 10^6$  cells/mL in DMEM, 20% FCS and 10% DMSO

### Background

Retroviruses are efficient tools for delivering heritable genes into the genome of dividing cells. However, conventional NIH-3T3 based retroviral packaging cell lines have limited stability and produce low viral yields, mainly due to poor expression level of the retroviral structure proteins (gag, pol, env) in the packaging cells.

The Platinum-A (Plat-A) Cell Line, a potent retrovirus packaging cell line based on the 293T cell line, was generated using novel packaging constructs with an EF1 $\alpha$  promoter to ensure longer stability and high-yield retroviral structure protein expression (gag, pol, amphotropic env). Plat-A cells can be kept in good condition in for at least 4 months in the presence of drug selection, and can produce retroviruses with an average titer of  $1 \times 10^6$  infectious units/mL by transient transfection. In addition, replication competent retroviruses (RCR) are virtually nonexistent because only coding sequences of viral structural genes are used, avoiding any unnecessary retroviral sequences.

The Plat-A cell line is designed for rapid, transient production of high-titer, amphotropic retrovirus.



**Figure 1.** TF-1 cells were infected with GFP retrovirus supernatant produced in Plat-A cells after transfection with pMX-GFP.

## Medium

1. Culture Medium: DMEM, 10% fetal calf serum (FCS), 1 µg/mL puromycin, 10 µg/mL blasticidin, penicillin and streptomycin
2. Freeze Medium: 70% DMEM, 20% FBS, 10% DMSO

## Methods

### **I. Establishing Plat-A Cultures from Frozen Cells**

1. After quickly thawing the cells in a 37°C water bath, immediately transfer the thawed cell suspension into a 15 mL tube containing 10 mL of culture medium.
2. Centrifuge the tube for 5 min at 1300 to 1500 rpm.
3. Discard the supernatant and break the cell pellet by finger tapping.
4. Add a few drops of culture medium with gentle shaking and finger tap the tube a few times.
5. Add 2 mL of culture medium to the tube and gently pipet the cell suspension up and down twice.
6. Transfer the cell suspension to a 10 cm culture dish (Falcon® #3003 works well) containing 8 mL of culture medium.
7. Swirl the culture plate well to mix the cells, then incubate the cells for three days before expansion.

#### ***Important Notes:***

- ***Don't change the culture medium during the first three days. It is normal to see some cells floating after the first 24 hours.***
- ***Don't culture cells to complete confluency. Split cells 4X to 6X every two to three days when the culture reaches 70-90% confluency.***

### **II. Splitting the Cells**

*Note: Avoid forming bubbles as much as possible during this procedure.*

1. Wash cells once with PBS.
2. Add 4 mL of 0.05% Trypsin/0.5 mM EDTA solution to a 10 cm dish and incubate at 37°C for 3-5 min.
3. Remove the cells from the dish surface by tapping the rim of the culture dish.
4. Transfer 10 mL of the culture medium to a 50 mL tube.
5. Using the same pipette with some residual culture medium, wash the dish surface gently three times in 4 mL of the Trypsin/EDTA solution.
6. Gently pipette the cell suspension up and down 7 times and transfer the cell suspension into the 50 mL tube containing 10 mL medium from step 4.
7. Centrifuge the cells for 5 min at 1300-1500 rpm.
8. Discard the supernatant and break the cell pellet by finger tapping.
9. Add a few drops of culture medium with gentle shaking and finger tap the tube a few times.
10. Add 5 mL of culture medium and gently pipet the cell suspension up and down twice.
11. Add 15 mL of culture medium, then count and seed the cells. Typically  $10^7$  cells can be harvested from one 10 cm culture dish.

## **Transfection**

1. Seed  $2 \times 10^6$  cells in a 60 mm culture dish without antibiotics including puromycin and blasticidin one day before transfection.
2. After 16 to 24 hours, start transfection when the culture becomes 70-80% confluent.  
*Note: We suggest transfecting cells with FuGENE® Transfection Reagent (Roche Applied Science) or Lipofectamine™ Plus (Invitrogen). For example, 3 µg retroviral expression plasmid is mixed with 9 µL FuGENE® Transfection Reagent according to the manufacturer's recommendation. The mixed DNA- FuGENE® complex is added by dropwise into the culture media.*
3. Harvest retroviral supernatant 48 hours after transfection.

## **References**

1. Morita, S., Kojim, T., and Kitamura, T. (2000) *Gene Therapy* 7: 1063-1066.

## **Recent Product Citations**

1. Bai, T. et al. (2021). Establishment of human induced trophoblast stem-like cells from term villous cytotrophoblasts. *Stem Cell Res.* **56**:102507. doi: 10.1016/j.scr.2021.102507.
2. Mellis, I.A. et al. (2021). Responsiveness to perturbations is a hallmark of transcription factors that maintain cell identity in vitro. *Cell Syst.* **12**(9):885-899.e8. doi: 10.1016/j.cels.2021.07.003.
3. Lesch, S. et al. (2021). T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. *Nat Biomed Eng.* doi: 10.1038/s41551-021-00737-6.
4. Yang, C. et al. (2021). Nuclear IGF1R interacts with NuMA and regulates 53BP1-dependent DNA double-strand break repair in colorectal cancer. *Oncol Rep.* **46**(2):168. doi: 10.3892/or.2021.8119.
5. Kim, J. & Moon, Y. (2021). Mucosal ribosomal stress-induced PRDM1 promotes chemoresistance via stemness regulation. *Commun Biol.* **4**(1):543. doi: 10.1038/s42003-021-02078-1.
6. Hyun, Y.M. et al. (2020). Endogenous DEL-1 restrains melanoma lung metastasis by limiting myeloid cell-associated lung inflammation. *Sci Adv.* **6**(45):eabc4882. doi: 10.1126/sciadv.abc4882.
7. Petrova, S.C. et al. (2020). Regulation of breast cancer oncogenesis by the cell of origin's differentiation state. *Oncotarget.* **11**(43):3832-3848. doi: 10.18632/oncotarget.27783.
8. Nitta, S. et al. (2020). Three-dimensional spheroid culture of canine hepatocyte-like cells derived from bone marrow mesenchymal stem cells. *Regen Ther.* doi: 10.1016/j.reth.2020.09.002.
9. Luanpitpong, S. et al. (2020). A novel TRPM7/O-GlcNAc axis mediates tumour cell motility and metastasis by stabilising c-Myc and caveolin-1 in lung carcinoma. *Br J Cancer.* doi: 10.1038/s41416-020-0991-7.
10. Putri, D.S. et al. (2020). Cytomegalovirus infection elicits a conserved chemokine response from human and Guinea pig amnion cells. *Virology.* doi: 10.1016/j.virol.2020.06.005.
11. Ngan, H. et al. (2020). Erlotinib sensitivity of MAPK1p.D321N mutation in head and neck squamous cell carcinoma. *npj Genom. Med.* **5**:17. doi: 10.1038/s41525-020-0124-5.
12. Chan, A.W. et al. (2020). Receptor tyrosine kinase fusions act as a significant alternative driver of the serrated pathway in colorectal cancer development. *J Pathol.* doi: 10.1002/path.5418.
13. Nitta, S. et al. (2020). Conversion of mesenchymal stem cells into a canine hepatocyte-like cells by Foxa1 and Hnf4a. *Regen Ther.* **14**:165-176. doi: 10.1016/j.reth.2020.01.003.
14. Tang, F. et al. (2019). LATS1 but not LATS2 represses autophagy by a kinase-independent scaffold function. *Nat Commun.* **10**(1):5755. doi: 10.1038/s41467-019-13591-7.

15. Chylinski, K. et al. (2019). CRISPR-Switch regulates sgRNA activity by Cre recombination for sequential editing of two loci. *Nat Commun.* **10**(1):5454. doi: 10.1038/s41467-019-13403-y.
16. Yousefi, Z. et al. (2019). Fc Receptor-Like 1 as a Promising Target for Immunotherapeutic Interventions of B-Cell-Related Disorders. *Biomarker Insights.* doi: 10.1177/1177271919882351.
17. Han, Z. et al. (2019). High levels of Daxx due to low cellular levels of HSP25 in murine cancer cells result in inefficient adenovirus replication. *Exp Mol Med.* **51**(10):122. doi: 10.1038/s12276-019-0321-4.
18. Ding, W. et al. (2019). Inhibition of long non-coding RNA-AWPPH decreases osteosarcoma cell proliferation, migration and invasion. *Oncology Letters.* doi: 10.3892/ol.2019.10898.
19. Liu, F. et al. (2019). Gp130 degradation induced by epirubicin contributes to chemotherapy efficacy. *Biochem Biophys Res Commun.* pii: S0006-291X(19)31776-0. doi: 10.1016/j.bbrc.2019.09.055.
20. El Khattabi, L. et al. (2019). A Pliable Mediator Acts as a Functional Rather Than an Architectural Bridge between Promoters and Enhancers. *Cell.* pii: S0092-8674(19)30776-7. doi: 10.1016/j.cell.2019.07.011.
21. Zyner, K.G. et al. (2019). Genetic interactions of G-quadruplexes in humans. *Elife.* 8. pii: e46793. doi: 10.7554/eLife.46793.
22. Mokuda, S. et al. (2019). Wwp2 maintains cartilage homeostasis through regulation of Adamts5. *Nat Commun.* **10**(1):2429. doi: 10.1038/s41467-019-10177-1.
23. Rataj, F. et al. (2019). High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy. *Br J Cancer.* **120**(1):79-87. doi: 10.1038/s41416-018-0341-1.
24. Kim, S.G. et al. (2019). Increase in the nuclear localization of PTEN by the Toxoplasma GRA16 protein and subsequent induction of p53-dependent apoptosis and anticancer effect. *J Cell Mol Med.* doi: 10.1111/jcmm.14207.
25. Salem, M. et al. (2019). GARP Dampens Cancer Immunity by Sustaining Function and Accumulation of Regulatory T Cells in the Colon. *Cancer Res.* **79**(6):1178-1190. doi: 10.1158/0008-5472.CAN-18-2623.
26. Tamari, K. et al. (2018). Polyamine flux suppresses histone lysine demethylases and enhances ID1 expression in cancer stem cells. *Cell Death Discov.* 4:104. doi: 10.1038/s41420-018-0117-7.
27. Kawamura, Y. et al. (2018). The role of Zfx2 transcription factor in bipolar cell differentiation during mouse retinal development. *Biochem Biophys Res Commun.* **503**(4):3023-3030. doi: 10.1016/j.bbrc.2018.08.088.
28. Flores-Villanueva, P.O. et al. (2018). An Isolated TCR  $\alpha\beta$  Restricted by HLA-A\*02:01/CT37 Peptide Redirecting CD8+ T Cells To Kill and Secrete IFN- $\gamma$  in Response to Lung Adenocarcinoma Cell Lines. *J Immunol.* **200**(8):2965-2977. doi: 10.4049/jimmunol.1701054.
29. Hu, H. et al. (2018). Long non-coding RNA XLOC\_000647 suppresses progression of pancreatic cancer and decreases epithelial-mesenchymal transition-induced cell invasion by down-regulating NLRP3. *Mol Cancer.* **17**(1):18. doi: 10.1186/s12943-018-0761-9.
30. Wang, Y. et al. (2018). Long non-coding RNA Inc-PCTST predicts prognosis through inhibiting progression of pancreatic cancer by downregulation of TACC-3. *Int J Cancer.* **143**(12):3143-3154. doi: 10.1002/ijc.31657.

### **Warranty**

These products are warranted to perform as described in their labeling and in Cell Biolabs literature when used in accordance with their instructions. THERE ARE NO WARRANTIES THAT EXTEND BEYOND THIS EXPRESSED WARRANTY AND CELL BIOLABS DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR WARRANTY OF

FITNESS FOR PARTICULAR PURPOSE. CELL BIOLABS 's sole obligation and purchaser's exclusive remedy for breach of this warranty shall be, at the option of CELL BIOLABS, to repair or replace the products. In no event shall CELL BIOLABS be liable for any proximate, incidental or consequential damages in connection with the products.

### **License Information**

This licensed product is intended for ACADEMIC, GOVERNMENT AND NON-PROFIT RESEARCH USE ONLY; not for use in diagnostic or therapeutic procedures. The product may not be transferred, sold, or otherwise provided to another laboratory except by an authorized distributor of Cell Biolabs, Inc.

Use of this product by Biotechnology and Pharmaceutical companies requires a license for all fields of use including research. Please contact:

Director of Business Development  
Cell Biolabs, Inc.  
[busdev@cellbiolabs.com](mailto:busdev@cellbiolabs.com)

### **Contact Information**

Cell Biolabs, Inc.  
7758 Arjons Drive  
San Diego, CA 92126  
Worldwide: +1 858-271-6500  
USA Toll-Free: 1-888-CBL-0505  
E-mail: [tech@cellbiolabs.com](mailto:tech@cellbiolabs.com)  
[www.cellbiolabs.com](http://www.cellbiolabs.com)

©2008-2021: Cell Biolabs, Inc. - All rights reserved. No part of these works may be reproduced in any form without permissions in writing.